A detailed history of Strs Ohio transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Strs Ohio holds 105,500 shares of AVIR stock, worth $349,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,500
Previous 105,500 -0.0%
Holding current value
$349,205
Previous $349,000 1.15%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$3.31 - $4.04 $35,748 - $43,632
10,800 Added 11.4%
105,500 $349,000
Q1 2024

May 13, 2024

SELL
$3.09 - $4.56 $18,540 - $27,359
-6,000 Reduced 5.96%
94,700 $382,000
Q2 2023

Jul 31, 2023

BUY
$3.21 - $5.06 $17,655 - $27,829
5,500 Added 5.78%
100,700 $376,000
Q1 2023

Aug 02, 2023

SELL
$3.0 - $4.97 $16,500 - $27,335
-5,500 Reduced 5.46%
95,200 $318,000
Q1 2023

Apr 27, 2023

SELL
$3.0 - $4.97 $98,100 - $162,519
-32,700 Reduced 25.57%
95,200 $318,000
Q4 2022

Jan 26, 2023

BUY
$4.35 - $6.17 $160,080 - $227,056
36,800 Added 40.4%
127,900 $615,000
Q3 2022

Oct 27, 2022

SELL
$5.49 - $8.79 $21,411 - $34,281
-3,900 Reduced 4.11%
91,100 $518,000
Q2 2022

Jul 25, 2022

SELL
$5.33 - $8.18 $152,971 - $234,766
-28,700 Reduced 23.2%
95,000 $674,000
Q1 2022

Apr 21, 2022

BUY
$5.5 - $9.19 $141,350 - $236,183
25,700 Added 26.22%
123,700 $893,000
Q4 2021

Jan 24, 2022

BUY
$7.67 - $44.59 $461,734 - $2.68 Million
60,200 Added 159.26%
98,000 $876,000
Q3 2021

Oct 22, 2021

BUY
$21.33 - $35.06 $14,930 - $24,542
700 Added 1.89%
37,800 $1.33 Million
Q2 2021

Jul 26, 2021

BUY
$19.22 - $59.08 $555,458 - $1.71 Million
28,900 Added 352.44%
37,100 $796,000
Q1 2021

Apr 23, 2021

BUY
$41.42 - $88.44 $194,674 - $415,668
4,700 Added 134.29%
8,200 $506,000
Q4 2020

Jan 25, 2021

BUY
$26.36 - $41.78 $92,260 - $146,230
3,500 New
3,500 $146,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $276M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.